Details for New Drug Application (NDA): 020912
✉ Email this page to a colleague
NDA 020912 describes AGGRASTAT, which is a drug marketed by Medicure and is included in two NDAs. It is available from one supplier. Additional details are available on the AGGRASTAT profile page.
The generic ingredient in AGGRASTAT is tirofiban hydrochloride. There are four drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the tirofiban hydrochloride profile page.
The generic ingredient in AGGRASTAT is tirofiban hydrochloride. There are four drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the tirofiban hydrochloride profile page.
Summary for 020912
| Tradename: | AGGRASTAT |
| Applicant: | Medicure |
| Ingredient: | tirofiban hydrochloride |
| Patents: | 0 |
Pharmacology for NDA: 020912
| Physiological Effect | Decreased Platelet Aggregation |
Suppliers and Packaging for NDA: 020912
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| AGGRASTAT | tirofiban hydrochloride | INJECTABLE;INJECTION | 020912 | NDA | Medicure International Inc | 25208-001 | 25208-001-04 | 1 VIAL, GLASS in 1 CARTON (25208-001-04) / 15 mL in 1 VIAL, GLASS |
| AGGRASTAT | tirofiban hydrochloride | INJECTABLE;INJECTION | 020912 | NDA | Medicure International Inc | 25208-901 | 25208-901-04 | 1 VIAL, GLASS in 1 CARTON (25208-901-04) / 15 mL in 1 VIAL, GLASS |
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | INJECTABLE;INJECTION | Strength | EQ 12.5MG BASE/50ML (EQ 0.25MG BASE/ML) | ||||
| Approval Date: | May 14, 1998 | TE: | RLD: | No | |||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | RX | Dosage: | SOLUTION;INJECTION | Strength | EQ 3.75MG BASE/15ML (EQ 0.25MG BASE/ML) | ||||
| Approval Date: | Aug 31, 2016 | TE: | RLD: | Yes | |||||
Expired US Patents for NDA 020912
Complete Access Available with Subscription
